Rainbow Children's Medicare Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹16,071 Cr
- Book Value
- ₹162
- Stock P/E
- 56.1
- Dividend Yield
- 0.22%
- ROE
- 15.9%
- ROCE
- 17.4%
- PEG Ratio
- 1.27
- EV/EBITDA
- 27.7
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Rainbow Children’s Medicare share price today
Rainbow Children’s Medicare (NSE: RAINBOW) is India’s only listed pediatric and perinatal hospital chain — children’s intensive care, neonatal ICUs, pediatric specialties and women’s health, delivered hub-and-spoke across Hyderabad, Bengaluru, Chennai, Delhi and beyond. The specialty focus is the moat: pediatric intensivists and neonatologists are scarce, parents don’t comparison-shop a sick child, and referral networks route the hardest cases to the specialist with the NICU beds.
Growth reflects both demand and expansion: 44% five-year profit CAGR with 31.6% operating margins — the flag notes the headline D/E of 0.54 is capitalised hospital leases, not borrowing stress. At 56.1× with a PEG of 1.27, our universe tags it wait: specialty scarcity, fully priced on ordinary days.
The specialist premium
General hospitals treat children; Rainbow is built for them — 24/7 pediatric emergency, child-sized everything, and the clinical outcomes that come from volume concentration in rare conditions. Birth-rate anxiety misreads the thesis: pediatric tertiary care is penetration-driven (insurance, urbanisation, parental spending), not birth-count-driven, and women’s-health services (fertility, high-risk obstetrics) feed the pediatric funnel by design. New units in north India climb their J-curves on schedule.
Watch-items: new-hospital ramp trajectories, clinician retention (the scarce input), payor-mix evolution, and any regulatory pricing intervention across private healthcare.
The numbers
From our research universe snapshot (5 Aug 2026):
| Metric | Value |
|---|---|
| Market cap | ₹16,071 Cr |
| P/E (TTM) | 56.1 |
| EV/EBITDA | 27.7 |
| Operating margin | 31.6% |
| ROE / ROCE | 15.9% / 17.4% |
| Debt to equity | 0.54 (capitalised leases) |
| Sales CAGR (5y) | 21.2% |
| Profit CAGR (5y) | 44.0% |
| Promoter holding | 49.8% |
| EPS (TTM) | ₹28.15 |
Rainbow Children’s share price target 2026 to 2030
EPS base ₹28.15 (TTM). Bear: ramps slow, pricing scrutiny lands — 12% growth, multiple at 32×. Base: the network compounds as new units mature — 18% growth at 45×. Bull: specialty scarcity premium extends nationally — 24% growth at 58×.
| Year | Bear (32×, +12%) | Base (45×, +18%) | Bull (58×, +24%) |
|---|---|---|---|
| 2026 | ₹1,010 | ₹1,495 | ₹2,025 |
| 2027 | ₹1,130 | ₹1,765 | ₹2,510 |
| 2028 | ₹1,265 | ₹2,080 | ₹3,115 |
| 2029 | ₹1,415 | ₹2,455 | ₹3,860 |
| 2030 | ₹1,590 | ₹2,900 | ₹4,785 |
From ₹1,579, the base case is ≈ +84% over four and a half years — and the bear case is flat (+1%), the staggered-J-curve cushion at work. The range below converts that asymmetry into an entry.
Reasons to own Rainbow (at the right price)
- The only listed pure-play on pediatric care — scarcity in listing and specialty both.
- Referral moats: the hardest cases route to the deepest NICU bench.
- 44% profit CAGR as new hospitals climb their J-curves.
- Women’s-health services feed the pediatric funnel structurally.
- PEG 1.27 for specialty-hospital growth is reasonable against the sector.
The risks: clinician scarcity cuts both ways (retention is existential), healthcare pricing is a standing political target, and lease-heavy expansion needs each ramp to perform.
Should you buy at the current price?
The live buy range below is for members — specialist care, generalist price.
FAQ
What is the Rainbow Children’s share price target for 2030? Base case ≈ ₹2,900 (45× on 18% compounded growth), bear ≈ ₹1,590, bull ≈ ₹4,785. Arithmetic above.
Doesn’t a falling birth rate hurt Rainbow? Volume in pediatric tertiary care comes from penetration — insurance coverage, urbanisation, willingness to pay for specialists — which is rising far faster than birth counts are drifting.
Why is the D/E 0.54 flagged as benign? Accounting standards capitalise long hospital leases as debt. Rainbow’s actual borrowings are modest; the ratio reads worse than the balance sheet lives.
When are Rainbow’s next results? Track the exact date on our results calendar.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.